QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

• Status: Withdrawn
• Trial end date: 2019-03-01

Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with NSCLC who have progressed on or after treatment with PD-1/PD-L1 inhibitors.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: ImmunityBio, Inc.; NantCell, Inc.
• Treatments: Avelumab; Bevacizumab; Capecitabine; Cisplatin; Cyclophosphamide; Fluorouracil; Fulvestrant; Leucovorin; Nivolumab; Oxaliplatin; Paclitaxel; Vaccines